Evaluating only Unum Therapeutics’s profile at its peak — without knowing the outcome — the model ranked Unit economics as the #1 likely cause. Documented cause: Regulation.
Key Events Timeline
FOUNDING
Founded in Cambridge, MA, to develop antibody-coupled T-receptor (ACTR) T-cell immunotherapy for cancer.
FUNDING
Raised $60M Series B to advance ACTR707 into Phase 1/2 trials at major cancer centers.
REGULATORY ACTION
FDA placed clinical hold on ACTR707 after patient death; company halted enrollment at Dana-Farber.
SHUTDOWN
Unum announced complete shutdown and wind-down, unable to raise capital to continue operations.
Full Analysis
Free · no account needed
Documented cause
Unum Therapeutics developed ACTR T-cell therapy for B-cell lymphoma. In May 2019, FDA placed a clinical hold on ACTR707 after a patient death in its Phase 1/2 trial at Dana-Farber Cancer Institute. The hold was lifted in August 2019 but investor confidence collapsed. By February 2020, having raised $111M total, Unum announced complete shutdown and liquidation, unable to raise further capital.
Lesson
“Early-phase safety deaths can permanently freeze capital access even after regulatory holds are lifted.”